Biotech News

Processa Pharmaceuticals Provides Portfolio and Business Update

Processa Pharmaceuticals (PCSA)Processa Pharmaceuticals2026-06-25 13:46 ESTCompany update

PCSA (PCSA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is pcsa.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

PCSAProcessa Pharmaceuticals2026-06-25 13:46 EST

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

PCSAProcessa Pharmaceuticals2026-06-25 13:46 EST

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

PCSAProcessa Pharmaceuticals2026-06-25 13:46 EST

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

PCSAProcessa Pharmaceuticals2026-06-25 13:46 EST

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

PCSAProcessa Pharmaceuticals2026-06-25 13:46 EST

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

PCSAProcessa Pharmaceuticals2026-06-25 13:46 EST

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

PCSAProcessa Pharmaceuticals2026-06-25 13:46 EST

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

PCSAProcessa Pharmaceuticals2026-06-25 13:46 EST

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

PCSAProcessa Pharmaceuticals2026-06-25 13:46 EST

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Processa Pharmaceuticals

Processa Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

PCSAProcessa Pharmaceuticals2026-06-26 07:33 EST

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

PCSAProcessa Pharmaceuticals2026-06-26 07:33 EST

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

PCSAProcessa Pharmaceuticals2026-06-26 07:33 EST

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

PCSAProcessa Pharmaceuticals2026-06-26 07:33 EST

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

PCSAProcessa Pharmaceuticals2026-06-26 07:33 EST

Processa Pharmaceuticals Provides Portfolio and Business Update

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States